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Introduction
Hepcidin plays a central role in iron metabolism, and could
become a useful biomarker for the diagnosis and monitoring of
iron disorders.1,2 Progress in human studies of hepcidin in normal
physiology and various disease states has been hampered by the
limited availability of hepcidin assays. Assays have been devel-
oped on mass spectrometry platforms including surface
enhanced laser desorption/ionization time-of-flight mass spec-
trometry (SELDI-TOF MS), matrix assisted laser desorption/ion-
ization time-of-flight mass spectrometry (MALDI-TOF MS) and
liquid chromatography tandem-MS techniques (LC-MS/MS).
Some methods use an internal standard, either hepcidin analogs
or bioactive hepcidin-25 synthesized with stable isotopes.3-10
Recently, immunochemical (IC) assays for hepcidin-25 have also
been developed, which comprise of competitive radio-
immunoassays (RIA)11 and enzyme-linked immunosorbent
assays (ELISA).12,13 Currently there is no reference method for
hepcidin measurements. Therefore, to increase comparability of
hepcidin data across clinical studies we evaluated the levels,
between-sample variation and the analytical variation of hep-
cidin assays on a panel of urine and plasma samples in a so-called
Round Robin.14
Design and Methods
Study design and participants
A prospective repeated measurement design with 12 replicates
was used to assess concordance in urine and plasma hepcidin
The recently discovered iron regulatory peptide hormone
hepcidin holds promise as a novel biomarker in iron
metabolism disorders. To date, various mass spectrometry
and immunochemical methods have been developed for its
quantification in plasma and urine. Differences in method-
ology and analytical performance hinder the comparability
of data. As a first step towards method harmonization,
several hepcidin assays were compared. Worldwide eight
laboratories participated in a urinary and plasma round
robin in which hepcidin was analyzed. For both urine and
plasma: (i) the absolute hepcidin concentrations differed
widely between methods, (ii) the between-sample varia-
tion and the analytical variation of the methods are similar.
Importantly, the analytical variation as percentage of the
total variance is low for all methods, indicating their suit-
ability to distinguish hepcidin levels of different samples.
Spearman correlations between methods were generally
high. The round robin results inform the scientific and
medical community on the status and agreement of the
current hepcidin methods. Ongoing initiatives should facil-
itate standardization by exchanging calibrators and repre-
sentative samples. 
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analysis. Six and eight laboratories participated in the uri-
nary and plasma analyses, respectively, in six different
countries. The study was coordinated by the Department
of Clinical Chemistry of the Radboud University
Nijmegen Medical Centre. All laboratories performed 12
replicates, that consisted of triplicate assays of each sample
on four consecutive days. The only information provided
about the samples were urinary creatinine levels. 
Specimens
Eight urine samples with a wide range of hepcidin con-
centrations were collected from healthy subjects (samples
1-5) and patients (samples 6-8) (October 2007) with
informed consent according to the declaration of Helsinki.
Synthetic hepcidin-25 (Peptide Institute Inc., Osaka, Japan,
net hepcidin peptide weight is precisely determined by
amino acid analysis after acid hydrolysis) was added to a
final concentration of 13.1 nmol/mmol creatinine to a
urine sample that by SELDI-TOF MS7 was found to have a
hepcidin concentration below the lower limit of detection
of 0.5 nmol/L (sample 5). Seven plasma pools were com-
posed from hospitalized patient sample remnants (March
2008), so as to cover a wide variation in hepcidin levels
(samples 9-15). All samples were centrifuged for 10 min at
2600 g, and immediately stored in aliquots at –80°C. Two
weeks after collection and storage, the samples were
shipped on dry ice to all participants, and measured with-
in four weeks of receipt, except for method VI (see below),
that was carried out in July 2008. All samples underwent
only one freeze-thaw cycle before analysis to minimize
changes that may differently affect the various methods,
among which are the formation of hepcidin aggregates and
breakdown products. 
Hepcidin methods
Characteristics of the methods used for the plasma and
urine hepcidin measurements of the present study are
schematically presented in Table 1. 
Method I is based on SELDI-TOF MS. Samples were
directly applied to hydrophilic Normal Phase chips (NP20
ProteinChip; Bio-Rad Laboratories). Synthetic 25-hepcidin
(Peptide Institute Inc.) was used for external mass calibra-
tion. 
Method II is also based on SELDI-TOF MS. Hepcidin was
first extracted from the sample using Macro-Prep® CM
Support beads (Bio-Rad Laboratories). The extract was
applied to NP20 chips (Bio-Rad Laboratories). Synthetic
hepcidin-24 peptide (custom made, Peptide Institute Inc.)
was used as an internal standard. 
For method III, urine samples were de-salted using C8
Clinprot beads (Bruker Daltonik) and analyzed by MALDI-
TOF MS. Plasma samples were assayed by SELDI-TOF-
MS using Cu2+ loaded IMAC chips. Synthetic human hep-
cidin-25 (Peptide Institute Inc.) was used as an external
standard in both assays.
Method IV is based on LC-MS/MS. [15N,13C2]Gly12,20 hep-
cidin (heavy hepcidin) was added to plasma or urine as
internal standard. Magnetic nanoparticles (Bruker
Daltonik) were used to extract hepcidin from the samples
followed by LC-MS/MS analysis using selected reaction
monitoring of the triple charged precursor fragmenting to
the double charged product ion for both heavy hepcidin
and hepcidin.
Method V is a competitive ELISA. 96-well plates were
coated with in house-prepared anti-human hepcidin anti-
body and biotinylated hepcidin-25 as tracer. Custom syn-
thesized hepcidin-25 was used as an external standard. 
Method VI is a competitive RIA using a 125I labeled syn-
thetic hepcidin-25 (Bachem) with an in-house rabbit anti-
hepcidin polyclonal antibody (against hepcidin-KLH con-
jugate) using a secondary antibody-PEG assisted separa-
tion. Synthetic hepcidin-25 (Bachem) was used as an exter-
nal standard. 
Method VII is based on LC-MS/MS. Isotopic human syn-
thetic hepcidin-25 (Peptide Institute Inc.) was used as an
internal standard.
Method VIII is a competitive ELISA: plates were coated
with an in -house prepared hepcidin-25-His peptide and a
polyclonal antibody against recombinant (in-house pre-
pared) hepcidin-25-His was used to establish competition.
Horseradish peroxidase labeled anti-rabbit antibody was
used as secondary antibody. Hepcidin-25-His was used as
an external standard.
Statistical methods 
The study was designed to compare hepcidin levels as
well as the repeatability of the methods used for serum
and urine, respectively. With respect to the repeatability,
the magnitude of variation that exists between samples
and between measurements of the same sample relative to
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Table 1. Characteristics of methods used for plasma and urine hepcidin measurements. 
Method Principle Method Hepcidin extraction Standard Urine Plasma
I Mass spectrometry SELDI-TOF MS Normal phase None X X
II Mass spectrometry SELDI-TOF MS Weak cation exchange Internal Synthetic hepcidin-24 X X
III Mass spectrometry MALDI-TOF MS Reversed phase External Synthetic hepcidin-25 X
SELDI-TOF MS Immobilized metal affinity External Synthetic hepcidin-25 X
Chromatography
IV Mass spectrometry LC-MS/MS Weak cation exchange Internal [15N,13C2]Gly-12,20-hepcidin X X
V Immunochemical Competitive ELISA None External Synthetic hepcidin-25 X X
VI Immunochemical Competitive RIA None External Synthetic hepcidin-25 X X
VII Mass spectrometry LC-MS/MS None Internal Synthetic hepcidin-25 X
VIII Immunochemical Competitive ELISA None External Recombinant hepcidin-25-His X
X: participation in hepcidin round robin for urine and/or plasma.
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the total variation are of interest. Accordingly, we parti-
tioned the total variance of each hepcidin method into the
following components: i) the between-sample variance and
ii) the analytical variance. Our design allowed us to divide
the latter into three subcomponents: the between-day vari-
ance, the between triplicate variance and the residual ana-
lytical variance, i.e. the part of the analytical variance that
cannot be attributed to the other two.
A linear mixed model was used to estimate these vari-
ance components of each method separately. The depend-
ent variable was hepcidin outcome, and the independent
random variables were: sample (plasma: 7 levels, urine: 8
levels), day (4 levels) and repeated measurement (3 levels).
We found that the estimated percentage variance due to
the triplicate measurements was very small and consider-
ably smaller than the variance due to the between-day vari-
ation. Consequently, this term was omitted from the final
model and not presented separately. The SD (absolute
error), the CV (relative error) and the percentage variance
relative to the total variance of each random variable are
presented and for each method separately.
Results and Discussion
Mean hepcidin levels for all (Table 2) samples differ
considerably between all methods.
Notably, hepcidin values of method V are relatively high,
but trends and variability are similar to all other methods
(Table 2). It is also of note that for this Round Robin study,
we only used native urine and serum samples, except for
one, i.e. urine sample 5 to which synthetic hepcidin was
added to a final concentration of 13.1 nmol/mmol creati-
nine. We found that the mean hepcidin outcome of some
methods (i.e. methods II, IV and VI) for this spiked urine
sample are closer to this concentration than others.
However, irrespective of whether the value assigned of the
spiked hepcidin-25 by Peptide International is correct,
these results can not simply be extrapolated to native urine
or serum samples, since it is presently unclear whether the
various methods evaluated behave differently for spiked
and native samples. In other words, the so called com-
mutability of the spiked samples with native clinical sam-
ples for the various methods is unknown and its assess-
ment may be part of future standardization efforts for hep-
cidin measurements.15
In general, differences in hepcidin levels between meth-
ods might be due to: (i) the use of different calibration solu-
tions with level assignments based on different techniques;
(ii) to hepcidin aggregation of either the standard solution
or the sample; or (iii) hepcidin binding to α2 macroglobuline
or albumine16 or (iv) the existence of three hepcidin iso-
forms hepcidin-25, 22 and 20. These four points may dif-
ferentially affect IC and MS measurements, and urine and
serum quantifications. More specifically, it was recently
found that around 90% of the circulating hepcidin is bound
to α2 macroglobulin in the blood. These observations not
only raise the question whether we should measure total,
bound or unbound hepcidin, but also what the methods
evaluated actually measure. The search for an answer to
these questions is a new challenge for which much can be
learned from the measurements of steroid and thyroid hor-
mones. Another cause for differences between IC and MS
methods is that IC methods lack the selectivity to distin-
guish hepcidin-25 from hepcidins-20 and -22. However, the
implications of including the latter two isoforms in the
Table 2. Mean (±SD) urine and plasma hepcidin levels presented by sample ID and method.
Method I# Method II Method III Method IV Method V Method VI Method VII Method VIII
Body Sample Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
fluid
Urine 1 0.04 (0.01) < LLOD − 0.6 (0.4) 1.0 (0.6) 1.5 (0.3) 0.2 (0.01)9 − − − −
2 0.2 (0.1) 0.4 (0.1) 4.4 (4.0) 2.2 (0.7) 14.1 (0.5) 3.2 (0.2)9 − − − −
3 0.5 (0.1) 0.6 (0.1) 1.9 (0.6) 2.4 (0.7) 19.0 (4.2) 2.3 (0.4)9 − − − −
4 0.6 (0.2) 1.9 (0.4) 7.0 (0.7) 3.7 (1.1) 105.8 (176.0) 8.3 (1.0)9 − − − −
5 1.2 (0.4) 12.0 (3.0) 27.1 (6.7) 14.7 (1.9) 115.4 (14.9) 12.1 (0.9)9 − − − −
6 2.7 (0.5) 48.6 (6.3) 2.7 (0.6) 51.2 (14.7) 861.6 (308.2) 14.3 (1.6)9 − − − −
7 6.3 (1.2) 35.1 (6.5) 14.4 (3.3) 52.9 (11.5) 659.6 (176.4) 12.9 (1.2)9 − − − −
8 11.6 (2.7) 184.8 (36.0)11 49.2 (8.7) 153.0 (21.9) 1646.9 (597.1) 13.7 (0.9)9 − − − −
Plasma 9 < LLOD − < LLOD − 0.2 (0.6) 1.1 (0.4) 2.4 (3.8) 0.5 (0.1) 0.3 (0.1) 61.1 (6.6)
10 4.6 (1.8) 4.3 (0.3) 14.3 (2.7) 7.1 (0.6) 39.7 (10.7) 9.4 (0.5) 4.1 (0.7) 32.7 (4.9)
11 4.1 (1.0) 5.6 (1.1) 16.2 (2.6) 7.2 (0.5) 61.3 (12.9) 9.9 (0.8) 4.6 (0.7) 19.4 (2.7)
12 7.5 (3.2) 8.4 (0.6) 23.4 (3.4) 14.1 (0.7) 128.9 (46.2) 21.2 (1.4) 9.3 (1.7) 23.1 (2.8)
13 8.7 (3.6) 7.6 (2.4) 24.9 (3.9) 15.0 (1.0) 100.9 (53.5) 23.3 (0.9) 10.1 (1.8) 43.3 (5.4)
14 18.3 (5.6) 23.8 (3.6) 52.6 (9.0) 34.7 (1.6) 259.5 (37.0) 29.6 (1.5) 29.2 (5.9) 58.0 (5.2)
15 25.1 (6.0) 28.2 (2.6) 59.9 (12.2) 35.7 (1.5) 279.7 (44.2) 27.2 (2.0) 29.3 (4.0) 52.6 (6.7)
n,number of measurements if different from 12 (i.e., 3 measurements on four different days); urine results in nmol/mmol creatinine,plasma results in nmol/L; 1 nmol 
hepcidin-25=2.789 µg hepcidin-25; #,Results reported in arbitrary Units, e.g.Mint/mmol creatinine for urine and in Mint/L for plasma; < LLOD,below lower level of detection,
for method I: signal/noise < 3, for method II : < 50 pM and < 0.5 nM for urine and plasma, respectively.Mass spectrometry methods are highlighted in black.
assay on the total hepcidin values reported in the various
iron disorders are not yet known.
Most methods are similar in both analytical variation
and between-sample variation (Table 3). Of note is that the
between-sample CV is lower for plasma than for urine
hepcidin. This might indicate that the difference between
urine and plasma is not due to the method, but more to
biological mechanism, e.g the hepcidin excretion path-
ways. MS methodologies II, IV and VII, exploiting an inter-
nal standard, show slightly lower contribution of the ana-
lytical variance to the total variance compared to the other
MS methods I and III. These findings corroborate the
assumption that the use of an internal standard decreases
the analytical variation of the MS-techniques. IC-method
V shows a high between-sample CV in combination with
a relatively high analytical CV. Furthermore, IC-methods
VI and VIII express the lowest between-sample CV com-
pared to all other methods. However, both methods also
display low analytical variation. This relatively low
between-sample variation of both the latter IC-methods
illustrates the difficulties in the generation of specific anti-
bodies for hepcidin. 
Importantly, the contribution of the analytical variation
to the total variance is low for all methods (Table 3), which
indicates the potential suitability of all methods to distin-
guish hepcidin levels of different samples. However, of
note is that the higher the analytical variation of a method
the lower the probability that populations with only small
differences in hepcidin levels can be distinguished, e.g.
hepcidin levels of healthy controls from that of patients
with low-grade inflammation due to the presence of fea-
tures of the metabolic syndrome. 
Spearman correlations between the individual sample
mean hepcidin values obtained by most methods were
generally high (range 0.62-1.00), except for correlations
with method VIII that are somewhat disappointing (range
0.04-0.18). This should be interpreted with caution due to
the small number of samples analyzed (n=7 and n=8 for
plasma and urine, respectively). 
In summary, hepcidin levels reported by the various
methods vary considerably but analytical variance is gen-
erally low and similar for all methods. We recommend fur-
ther harmonization of the various hepcidin assays by: (i)
introducing an internal standard for all the MS-based
methods used for clinical studies; (ii) reaching consensus
on level assignment and level adjustment of the calibrators
used in every procedure; (iii) production of a calibrator that
mimics patient sera and (iv) regular testing of shared sam-
ples and/or calibrators that are commutable and have been
value assigned for quality control. 
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Table 3. Sample means and variations by method for urine and plasma hepcidin levels.
Analytical variation
Between-sample Between-day Residual analytical variation
Body fluid Method ‡Mean ALL ‡SD CV % of total ‡SD CV % of total ‡SD CV % of total
sample (%) variance (%) variance (%) variance
Urine I #2.9 #4.1 139.9 93.4 #<0.1 <0.1 <0.1 #1.1 37.3 6.6
II 44.4 66.1 148.8 95.9 4.9 11.0 0.5 12.8 28.9 3.6
III 13.4 16.9 125.9 93.7 1.8 13.3 1.1 4.0 29.8 5.2
IV 35.1 52.3 148.9 96.3 <0.1 <0.1 <0.1 10.2 29.1 3.7
V 427.1 587.8 137.6 85.4 102.8 24.1 2.6 220.6 51.6 12.0
VI 7.9 5.7 72.2 97.2 0.6 7.2 1.0 0.8 9.9 1.8
Plasma I #11.4 #8.4 73.6 81.3 #1.6 14.4 3.1 #3.7 32.2 15.6
II 13.0 10.3 79.1 96.0 0.4 3.2 0.2 2.1 15.8 3.9
0 27.4 21.3 77.9 92.1 0.7 2.6 0.1 6.2 22.6 7.6
IV 16.4 13.6 83.2 99.5 0.2 1.2 <0.1 1.0 6.0 0.5
V 124.6 107.0 85.8 89.4 26.1 20.9 5.3 26.0 20.8 5.3
VI 17.3 10.8 62.3 98.8 0.1 0.6 <0.1 1.2 6.8 1.2
VII 12.4 11.9 96.3 94.4 <0.1 <0.1 <0.1 2.9 23.4 5.6
VIII 41.5 16.7 40.2 90.9 3.1 7.5 3.1 4.3 10.4 6.0
Between-sample, segment due to variation between samples; analytical variation, segment due to repeated measurements; SD, standard deviation, i.e. absolute error;
CV: coefficient of variation, i.e. relative error; % of total variance,% of variance-segment to the total variance; ‡, sample means and SDs in nmol/mmol creatinine and
nmol/L for urine and plasma, respectively, unless otherwise stated; #,mean and SD in Mint/mmol creatinine for urine and in Mint/L for plasma.
Mass spectrometry methods are highlighted in black.
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